Identification of Flavone Derivative Displaying a 4'-Aminophenoxy Moiety as Potential Selective Anticancer Agent in

Giovanna Mobbili1, Brenda Romaldi2, Giulia Sabbatini1

  • 1Department of Life and Environmental Sciences, Marche Polytechnic University, 60131 Ancona, Italy.

Insights

New aminophenoxy flavone derivatives show promise as selective lung cancer treatments. Compound APF-1 effectively targets non-small cell lung cancer (NSCLC) cells while sparing healthy cells, indicating potential for novel anticancer drug development.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Flavone derivatives are explored for their therapeutic potential.
  • Lung cancer remains a significant global health challenge.
  • Developing selective anticancer agents is a key research area.

Purpose of the Study:

  • To synthesize and evaluate novel aminophenoxy flavone derivatives for anticancer activity.
  • To assess the cytotoxicity of these compounds against non-small cell lung cancer (NSCLC) cell lines.
  • To investigate the mechanism of action of the most promising derivative.

Main Methods:

  • Synthesis of five heterocyclic derivatives via functionalization of a flavone nucleus.
  • In vitro cytotoxicity assays (MTT assay) on A549 and NCI-H1975 NSCLC cells and healthy fibroblasts.
  • Flow cytometric analysis to determine apoptosis and cell cycle effects.

Main Results:

  • One derivative, APF-1, demonstrated significant efficacy at low micromolar concentrations against both NSCLC cell lines.
  • APF-1 exhibited a high selective index (SI), indicating preferential toxicity to cancer cells.
  • Flow cytometry revealed APF-1 induces apoptosis and G2/M cell cycle arrest, linked to p21 up-regulation.

Conclusions:

  • Aminophenoxy flavone derivatives, particularly APF-1, show potential as selective anticancer agents for NSCLC.
  • APF-1's mechanism involves inducing apoptosis and cell cycle arrest.
  • These compounds provide a promising foundation for developing novel flavone-based anticancer drugs.